DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




MRI Homepage

Bruker and the Champalimaud Foundation to develop first 18 Tesla UHF MR scanner Enable discovery of new contrast mechanisms

Whole body MR may support faster, less expensive cancer treatment planning A single scan for planning and staging, but challenges remain

Helium shortage could have deflating effect on MR industry Party City cites shortage as contributor to 45 stores closing

MR method could spare patients with skull lesions from CT, says study Could benefit children and pregnant women

Synaptive unveils dedicated head MR system, Evry Will help in assessing the role of MR in emergency departments

AI comparable to radiologists in prostate cancer detection accuracy Identifies and predicts aggressiveness using MR scans

New study shows value of 7T MR for evaluating MS progression Can detect cortical lesions better than conventional scanners

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

The benefits of intraoperative MR Q&A with Dr. John Huston Mayo Clinic neuroradiologist discusses what the advanced capabilities mean for patients – as well as providers

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

A new clinical study could prove
MR to be a possible replacement
for biopsies in prostate cancer

Could MR replace biopsies for prostate cancer detection?

by John R. Fischer , Staff Reporter
The Medical Research Council (MRC) and Cancer Research U.K. have invested £5.1 million in a new clinical study that may lead to MR replacing biopsies in the diagnosis of prostate cancer.

The study, titled RE-IMAGINE, will be the first to evaluate MR as an accurate option for detecting prostate cancer earlier and more reliably in population screenings, and will test its combination with emerging techniques such as machine learning and genomics as potential replacements to biopsies.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"MR will give us volume location and probability," Mark Emberton, a professor of interventional oncology at University College London who will be leading the study, told HCB News. "One could match this morphometric information with circulating DNA. We hope that RE-IMAGINE will generate a new risk stratification method. One that may not necessarily include biopsy procured tissue."

Biopsies often cause side effects in patients, including pain, bleeding, urine retention and infections that lead to sepsis. At the same time, current prostate-specific antigen (PSA) tests are unreliable for population screenings with the U.K. reporting a 75 percent rate of false positives and 15 percent of false negatives among men who undergo such exams for prostate cancer.

The study will utilize MR in combination with other high-tech diagnostic tests to determine if such partnerships can better predict disease progression in 1,000 patients with medium to high-risk cancers, as part of an effort to develop better alternatives to biopsies for directing the right patient to the right course of treatment.

Researchers also plan to test its ability to detect prostate abnormalities in 300 men between 60 and 75 who have never undergone a PSA test.

Much of the work behind the study will be based on research conducted and published in The Lancet last year by Emberton and his colleagues, who found that MR scans were capable of ruling out cancer in 27 percent of men who received a positive PSA result.

They also showed that MR could detect 18 percent more cases of serious prostate cancer in men with possible tumors by using scans to guide the biopsy needle to the correct location.

"MR gives us the best resolution of any imaging platform at the prostate level," said Emberton, noting that it is also a cost-effective tool for providers. "We are going to link the imaging phenotype to the underlying genetic and transcriptomic architecture. We are then going to follow the patients for life."

In addition to UCL, MRC has partnered with King’s College London, the Imperial College of London and at least 12 industry partners in this endeavor.

The study is one of four funded by MRC’s Stratified Medicine Initiative in which £16.8 million will go toward the development of new approaches for treating prostate cancer, kidney disease, alcoholic hepatitis and childhood arthritis.

MRI Homepage


murray ogilvie

MR for prostate tumor detection

April 15, 2018 11:11

Just diagnosed, Aug 2017, using MR. Trans Rectal Fusion Biopsy is so much more precise. Post surgery PSA is undetectable. Personal opinion is that this is the only way to go.

Log inor Register

to rate and post a comment

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.